UCB announced today that Dr Melanie Lee, executive vice president UCB and president UCB NewMedicines, will leave UCB at the end of August 2009 and pursue other interests. Upon her departure from UCB, Melanie Lee will join the Scientific Advisory Board of UCB.
UCB CEO Roch Doliveux said: “I want to thank Melanie Lee for her strong contribution to the growth of UCB and before that, Celltech. In 2008, Melanie and her team put in place the foundations of an innovative organization named UCB NewMedicines, UCB’s discovery research through to ‘proof of concept’ organisation. We are all committed to make this new organization a leading edge discovery engine.”
Melanie Lee has led both the discovery and research and development organizations. She has served for six years as a Board Director with Celltech and five years on UCB’s Executive Committee, and has worked tirelessly through four integrations.
In 2008, she put in place the structure for a new research organization – UCB NewMedicines – designed to maximise internal and external skills and technologies from discovery research through “proof of concept”.
UCB has initiated an external search for a new individual to lead UCB NewMedicines. The new president UCB NewMedicines will move the organisation beyond its current achievements to deliver UCB’s breakthrough phase.